Background: The prevalence and clinical impact on mortality of carbapenem-resistant Pseudomonas aeruginosa (CRPA) is unclear in Taiwan. We aim to clarify these clinical issues by using data from the Taiwan Surveillance of Antimicrobial Resistance (TSAR) program. Methods: Patients from five hospitals with their P. aeruginosa isolates collected by TSAR II-VII (2000e2010) program were considered as the potential study population. All patients with CRPA were enrolled as case patients. Patients with carbapenem-susceptible P. aeruginosa were randomly selected in a 1:1 ratio to case patients as control patients. CRPA isolates were tested for the presence of carbapenemase-producing genes. The clinical data were collected to identify risk factors for CRPA carriage and mortality of P. aeruginosa infection. Results: The overall prevalence of CRPA was 10.2% (349/3408), which increased significantly by the TSAR period (p Z 0.007). Among the 164 enrolled patients, the risk factor for carrying CRPA was previous fluoroquinolone exposure (p Z 0.004). The risk factors for mortality among 80 patients with infection by P. aeruginosa included: intensive care unit (ICU) setting, receipt of antifungal therapy, and presence of invasive devices (p Z 0.001, 0.010, and 0.017; respectively). Carbapenem resistance did not play a role. Among the 82 CRPA isolates enrolled in this study, 15 isolates were found to carry carbapenemaseproducing genes. Conclusion: In Taiwan, the prevalence of CRPA and carriage of carbapenemase-producing genes was high. However, carbapenem resistance did not play a role in the mortality of patients with P. aeruginosa infections.
Introduction
Pseudomonas aeruginosa is one of the most common pathogens causing nosocomial infections. The ability to develop multidrug resistance makes these infections difficult to treat, and they are associated with high mortality rates, ranging from 18% to 61%. 1 As the use of antimicrobial agents becomes more extensive, the emergence of multidrug-resistant P. aeruginosa (MDRPA) has also increased. Carbapenems have been the main antibiotics used against MDRPA. However, carbapenem-resistant Pseudomonas aeruginosa (CRPA) has also emerged and caused many nosocomial outbreaks. 2, 3 In recent years, several surveillance studies from the USA and Europe have reported increasing prevalence of CRPA isolates (an increase from 4% in the 1990s to 14e30% in the 2000s), and there are regional differences in rates. Carbapenem resistance is due to multiple mechanisms, including production of carbapenemases, over-expression of the efflux pump, or loss of outer membrane porins plus production of extended spectrum b-lactamase or AmpC blactamase. 7 Among these resistance mechanisms, production of carbapenemase is the most important because it was associated with higher mortality rates compared with noncarbapenemase-producing CRPA. 8 The reported carbapenemases in P. aeruginosa included nonmetallo-enzyme carbapenemase (NMC), Serratia marcescens enzyme (SME), Klebsiella pneumoniae carbapenemase (KPC), imipenemhydrolyzing b-lactamase (IMI), Guiana extended-spectrum b-lactamase (GES), imipenemase (IMP), Verona integronencoded metallo-b-lactamase (VIM), German imipenemase (GIM), Sao Paulo metallo-b-lactamase (SPM), New Delhi metallo-b-lactamase (NDM), and oxacillinase-48 (OXA-48), among which VIM has been the most predominant. 9 Although there have been many updated epidemiological and microbiological studies on CRPA in several countries, 4e6 there are only a few reports from Taiwan on the prevalence of CRPA. 9e11 In addition, the effect of carbapenem resistance on the outcome of P. aeruginosa infections and risk factors for acquiring CRPA in Taiwan remain obscure. Therefore, the current burden, clinical epidemiology, and specific interventions designed according to the identified risk factors to prevent the spread of CRPA in Taiwan are also unclear. The present study was designed to clarify the above clinical issues.
Patients and methods
Bacterial isolates and patients P. aeruginosa isolates were collected as part of the TSAR program from medical centers and regional hospitals in Taiwan. The participating hospitals and bacterial collection procedures of TSAR have been described in detail in previous reports.
12e14 The complete lists of P. aeruginosa isolates from TSAR II (2000) to VII (2010), and their source were retrieved first from the TSAR database. The site investigators of the TSAR participating hospitals were contacted to obtain their agreement to participate in the present study. After obtaining the approval of the Research Ethics Committee, patients with infection or colonization by CRPA from these hospitals were considered as case patients. Patients with infection or colonization by CSPA from the same hospital as the case patients were considered as the pool of control patients. A computer-generated random digital number table was used to randomly select the final control patients with a 1:1 ratio to case patients.
Antimicrobial susceptibility test
Antimicrobial susceptibilities to various antimicrobial agents, including amikacin, gentamicin, piperacillin, ticarcillin/clavulanic acid, piperacillin/tazobactam, ceftazidime, cefepime, aztreonam, imipenem, meropenem, ciprofloxacin, levofloxacin, minocycline, colistin, and chloramphenicol were determined by minimum inhibitory concentration (MIC) using the microbroth dilution method and interpreted according to the criteria suggested by the Clinical and Laboratory Standards Institute (CLSI). 15, 16 In this study, CRPA was defined as an isolate with imipenem and/or meropenem MICs !8 mg/mL. 17 The other P. aeruginosa isolates were considered as CSPA. 13 
Detection of carbapenemase-producing genes
All the CRPA isolates were subjected to detection of carbapenemase-encoding genes, including NMC, SME, KPC, IMI, GES, IMP, VIM, GIM, SPM, NDM-1, NDM-2 and OXA-48, using polymerase chain reaction (PCR) methods as previously described. 9 
Data collection
A standardized case report form was used to collect the relevant demographic, clinical, and microbiological data. The following data were recorded: age and sex; comorbidities and underlying diseases; presence of neutropenia (absolute granulocyte count of <500 granulocytes/mL) and use of immunosuppressive therapy (chemotherapy, radiotherapy, or immunosuppressive drugs); past hospitalization and invasive therapy (hemodialysis or chemotherapy) within the past year; previous antibiotic use within the last 15 days; patients' setting and source of isolates; colonization or infection of CRPA and sites of primary infection; clinical signs and laboratory data; antimicrobial treatment received and outcome. Empirical antimicrobial therapy was considered appropriate when the antimicrobial regimen included any active antimicrobial by in vitro susceptibility testing results administered during the infection episode.
Statistical analysis
Continuous variables were described as mean AE standard deviation (SD) and compared using the Student t test, or described as the median as well as range, and compared with the Wilcoxon rank-sum test if their distributions were not normal. Categorical variables were compared with a Chi-square test or Fisher exact test if the expected values were less than 10. Risk factors for colonization and allcause in-hospital mortality were identified using logistic regression models. Statistical analyses were performed using SAS 9.2 (SAS Institute, Cary, NC, USA). All tests were two-tailed and p < 0.05 was considered statistically significant.
Results
Descriptive epidemiology from the TSAR database A total of 3408 P. aeruginosa isolates were collected from 26 hospitals in TSAR IIeVII (2000e2010). Among these isolates, 349 (10.2%) were CRPA. There was a significant trend of increasing CRPA prevalence over this period (p Z 0.007) (Fig. 1) . Only 2.0% (7/349) of CRPA isolates were susceptible to imipenem, whereas 38.1% (133/349) were susceptible to meropenem. Colistin was the most effective antibiotic against CRPA isolates with a susceptibility of 93.90%. CSPA isolates were significantly more susceptible to piperacillin/tazobactam (93.40% vs. 68.19%), levofloxacin (88.75% vs. 38.68%), and amikacin (98.78% vs. 42.95%) compared to CRPA isolates.
Bacterial isolates tested for the presence of carbapenemase-producing genes
Eighty-two CRPA isolates from five hospitals and another 82 CSPA isolates from the same hospitals were enrolled in the present study. Among the 82 CRPA isolates, 15 (15/82, 18.3%) were found to carry carbapenemase-producing genes, which all belonged to the VIM family. Comparison of antimicrobial susceptibilities between the carbapenemase-positive and non-carbapenemase-producing CRPA isolates is listed in Table 1 . Isolates with carbapenemase genes were more resistant to various antibiotics than carbapenemase nonproducers except piperacillin/tazobactam, imipenem, aztreonam, and colistin. Among carbapenemase producers, the most susceptible antibiotic was colistin (100%). Among non-carbapenemase-producers, the most effective antibiotics were amikacin and colistin with a susceptible rate of 94.03% and 92.54%, respectively. For these tested CRPA isolates, all carbapenemase-producers were resistant to amikacin. The susceptibility to amikacin had a very high positive predictive value (PPV) for the non-carbapenemaseproducing isolates (PPV Z 100%).
Risk factors for carriage of CRPA
The medical records of the 164 index patients were reviewed. The mean age was 65 years, with a male to female ratio of 2.3:1. The most common underlying diseases were coronary artery disease and neurologic disease. More than half of the patients had prior hospitalization history, and most patients were hospitalized in general wards when their P. aeruginosa isolates were identified. Sputum was the most common specimen source, followed by urine.
Comparing patients with CSPA or CRPA isolates by univariate logistic analysis (Table 2) , patients with CRPA tended to have renal disease (p Z 0.044), be a colonizer only (p Z 0.044), and have prior carbapenem and fluoroquinolone exposure (p Z 0.018 and 0.004, data not shown). Using multivariate logistic analysis, previous fluoroquinolone exposure was the only independent risk factor for acquiring CRPA isolates [adjusted odds ratio (AOR), 4.64; 95% confidence interval (CI), 1.64e13.14, p Z 0.004].
P. aeruginosa infection and outcome
Among the 164 source patients colonized or infected with CRPA and CSPA, there were 93 P. aeruginosa infected patients, of whom 45.2% (42/93) were infected with CRPA and 54.8% (51/93) with CSPA. We randomly selected a total of 42 CSPA-infected patients with a 1:1 ratio (from the same hospital) to 42 CRPA-infected patients to analyze the risk factors for mortality of infection. The clinical data regarding the outcome of two patients with CRPA infection were missed and therefore were excluded from the final analysis (also, two corresponding patients with CSPA infection were excluded). For the 80 P. aeruginosa infected patients, the all-cause in-hospital mortality rate was 23.8%. The most common infection focus was urinary tract infection (39/80, 48.8%), followed by lower respiratory tract infection (25/80, 31.3%).
In the analysis of factors associated with mortality, variables considered include age and sex, comorbidities and underlying diseases, past hospitalization and invasive therapy, patients' setting and sites of primary infection, clinical signs and laboratory data, presence of invasive devices, and antimicrobial treatment received were tested ( Table 3) . By univariate analysis, patients with hepatobiliary disease, acquisition of P. aeruginosa while staying in ICUs, and prior exposure to antifungal treatment were associated with a higher mortality (p Z 0.016, 0.001, and 0.040, respectively). The severity of disease, including hypotension and presence of invasive devices, also led to poorer outcome (p Z 0.002 and 0.005, respectively). By multivariate logistic analysis, patients staying in ICUs, prior exposure to antifungal therapy and presence of invasive devices, remained independent risk factors for 
Discussion
CRPA has emerged as a significant pathogen worldwide, but the prevalence varied by geographic region, specimen source, patient age, patient setting, and selective pressure from broad spectrum antibiotics. 18 In the Carbapenem Antimicrobials Pseudomonas Isolate Testing At regional Locations (CAPITAL) surveillance program in the USA during 2010, the resistant rate ranged from 7.4% to 35.4%. 18 According to the Taiwan Nosocomial Infections Surveillance System, the proportion of CRPA isolates among all P. aeruginosa isolates in the ICUs of medical centers was 18.1% in 2011, which was higher than that identified by the present study (10.2%). 19 These varied results implied the prevalence of CRPA was different among different geographic areas, patient population, and clinical setting. Every institution should regularly monitor the resistant rate of pathogens and the antibiotics consumption, and integrate the information into infection control programs. 20 In the present study, the overall prevalence of CRPA from 2000 to 2010 in Taiwan was 10.2%. This prevalence was similar to previous surveillance. 10 During our study period, the prevalence of carbapenem resistance among P. aeruginosa isolates in Taiwan increased significantly. Several studies from other countries also showed the same finding in recent years. 21 In our study, CRPA were more resistant to multiple drugs than CSPA isolates, and the most effective antibiotic against CRPA isolates was colistin (100% susceptible). Carbapenem resistance may result from multiple mechanisms with or without the production of carbapenemase. In the carbapenemase-producing CRPA, metallo-b-lactamases (MBLs) have been reported from many countries, 22 suggesting that these enzymes are an important mechanism of carbapenem resistance among P. aeruginosa. MBLs belong to Ambler class B carbapenemases, and AIM (Adelaide imipenemase), GIM, IMP, NDM, SPM, and VIM type MBLs have been described globally. Among them, bla AIM belongs to subclass B3 and is a potential transferable gene, but is less known than the other subclass B1 MBLs. In a previous study in Taiwan during 2000e2002, the prevalence of MBLproducing CRPA among all CRPA isolates was 17e36%, which was higher than a recent report on CRPA from French ICUs during 2010. 7, 23 Similar to those studies, we detected MBL in 18.3% of the CRPA studied, and all were the VIMtype. 19, 20 Carbapenemase-producing CRPA exhibited higher rates of resistance to various antibiotics except colistin and piperacillin/tazobactam, which was similar to a previous study. 23 However, the MIC of carbapenemase-producing CRPA to piperacillin/tazobactam tended to be higher than noncarbapenemase-producing CRPA (MIC 50 , >32 vs. 4; MIC 90 , >32 vs. 16). Among carbapenemase-negative CRPA isolates, amikacin had a similar susceptibility rate to that of colistin, and the positive predictive value of amikacin susceptibility for MBL-negative CRPA was 100%. For CRPA isolates in Taiwan, amikacin-susceptibility may be a hint for the absence of MBL genes.
The risk factors for acquiring CRPA may be related to the host condition, infection control practice, and antimicrobial consumptions. 20, 24, 25 Our data showed that prior exposure to fluoroquinolone was the only independent risk factor for acquiring CRPA. The association between prior fluoroquinolone use and CRPA isolates has been well established in previous studies. 26, 27 Exposure to fluoroquinolone leads to upregulation of the multidrug efflux pump MexEF-OprN and reduced levels of OprD porin, 28 with subsequent resistance to both fluoroquinolones and carbapenems. 7, 23, 27 In Taiwan, we noted an increase in the use of piperacillin/tazobactam, broad-spectrum cephalosporins, carbapenems, and fluoroquinolones. 20, 24 To reduce the prevalence of CRPA, it would be important to prescribe flluoroquinolones prudently.
Several studies have found higher mortality rates of P. aeruginosa infection to be related to patients' comorbidity, the site of primary infection, disease severity, multidrug resistance, and inappropriateness of empirical therapy. 29, 30 In this study, the independent risk factors for all-cause inhospital mortality in patients with P. aeruginosa infection were ICU stay, prior exposure to antifungal agents, and presence of invasive devices. All the independent risk factors in our study were indicators of severe comorbidities and illness. The critically ill patients who need ICU admission are associated with higher disease severity and inhospital mortality rate. 31 Fungal infection and antifungal therapy is related to more severe comorbidities including neoplasm with immunosuppressive agents, prior severe infection requiring the use of broad-spectrum antibiotics, and receiving aggressive surgery. 32 Invasive catheters are important tools in critically ill patients, and their widespread use may lead to several complications, significant morbidity, and mortality. 33 Our study did not find carbapenem resistance or inappropriate treatment as a significant factor associated with the mortality of patients infected with P. aeruginosa. Several retrospective studies suggested higher mortality rates among patients infected by nonsusceptible P. aeruginosa isolates. 25, 34 However, a few prospective cohort studies also showed that carbapenem resistance did not have a significant impact on mortality. 17, 35 In addition, some studies did not find an adverse impact of inappropriate therapy on mortality. 17, 25 The insignificant effect of carbapenem resistance and inappropriate treatment on patient outcome might result from the fact that the outcome of an infection is mostly dependent on the severity of the underlying disease, the primary site of infection, and the virulence of the pathogens. 17, 36 Some in vitro studies suggested that the resistance mutations can alter the fitness of microorganisms and make them less virulent, but the impact of resistance mutations on the virulence of clinical isolates has yet to be elucidated. 37, 38 Our study has several limitations. Firstly, this was a retrospective cohort study. The retrospective nature with a 1:1 matched ratio may preclude accurate comparisons because of many confounding factors such as underlying disease, severity of infection, occult bias, and other hidden confounding factors. To diminish these biases, we recorded related factors in detail and used multivariate logistic analysis to find the independent risk factors. However, our study results need further investigation for verification. Secondly, although we detected the presence of carbapenemase producing genes, its association with outcome was not investigated due to the small sample size. Further studies should be performed to clarify if the presence of carbapenem-resistance genes affects the clinical outcome. 38 Thirdly, the overall prevalence of CRPA was calculated using the data from the TSAR program. Different TSAR periods enrolled different hospitals. This might lead to the comparison of TSAR IIeVII from data of different hospitals. However, 18 hospitals continuously and consistently participated in the TSAR IIeVII program, but there were 13 hospitals not consistently participating in the TSAR program. The effect of different hospitals was not considered to be major. Finally, our study was conducted in Taiwan, and the situation may differ in other countries.
In conclusion, the CRPA prevalence in Taiwan was higher than in previous studies. However, the proportion of carbapenemase producers among CRPA was similar. ICU admission, prior antifungal therapy, and the presence of invasive devices are three factors independently associated with the all-cause in-hospital mortality of P. aeruginosa infection in our study. Contrary to previous beliefs, the mortality was not related to carbapenem resistance and appropriate treatment.
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